Compare GKOS & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | TECH |
|---|---|---|
| Founded | 1998 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 11.4B |
| IPO Year | 2015 | 1995 |
| Metric | GKOS | TECH |
|---|---|---|
| Price | $173.00 | $72.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 13 |
| Target Price | ★ $198.69 | $70.50 |
| AVG Volume (30 Days) | 723.3K | ★ 2.8M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 0.44% |
| EPS Growth | N/A | ★ 152.17 |
| EPS | N/A | ★ 1.16 |
| Revenue | $507,442,000.00 | ★ $1,215,039,000.00 |
| Revenue This Year | $36.18 | $4.35 |
| Revenue Next Year | $23.04 | $10.04 |
| P/E Ratio | ★ N/A | $62.46 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $43.20 |
| 52 Week High | $191.62 | $72.69 |
| Indicator | GKOS | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 56.54 | 55.79 |
| Support Level | $148.39 | $72.36 |
| Resistance Level | $184.68 | $72.66 |
| Average True Range (ATR) | 6.50 | 0.16 |
| MACD | 1.09 | -0.05 |
| Stochastic Oscillator | 89.32 | 47.67 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.